HomeHealthcareBiotechnology Tuberculosis Testing Market

Tuberculosis Testing Market Size, Share & Trends Analysis Report By Diagnostic Test Type (Radiographic Test, Smear Microscopy, Culture-Based Test, Nucleic Acid Test, Cytokine Detection Test, Drug Resistance Test, Other Diagnostic Test Types), By End User (Hospital/Clinic, Diagnostics/Research) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: November 03, 2026 | Author: Dhanashri Chandgude | Format:

Tuberculosis Testing Market Size & Growth Analysis

The global tuberculosis testing market size was valued at USD 2.07 billion in 2025 and is projected to grow from USD 2.18 billion in 2026 to USD 3.35 billion by 2034, registering a CAGR of 5.5% during the forecast period (2026–2034). North America dominated the tuberculosis testing market with a share of 36.5% in 2025.

Tuberculosis is a disease caused by bacteria of the genus mycobacteria. It mainly targets the lungs, but bacteria can also attack other body parts and cause infection of the genitourinary system, lymphatic system, and central nervous system. Pulmonary tuberculosis is a bacterial infection in the lungs, while infection in other body parts is extrapulmonary tuberculosis.

Tuberculosis Testing Market Key Takeaways

Global Market Size & Growth

2025 Market Size
USD 2.07 Billion
2026 Market Size
USD 2.18 Billion
2034 Projected Market Size
USD 3.35 Billion
Forecast Period
2026–2034
Base Year
2025
Market CAGR (2026–2034)
5.5%

Regional Insights

Largest Regional Market (2025)
North America
North America Market Share (2025)
36.5%
Fastest-growing Region
Asia Pacific
Asia Pacific CAGR (2026–2034)
6.74%

Segment Insights

By Diagnostic Test Type
Leading Segment
Nucleic Acid Test
Market Share in 2025 24.9%
By End User
Fastest-growing Segment
Diagnostics/Research
CAGR 5.72% (2026–2034)
Tuberculosis Testing Market Size , Share and Growth Forecast 2026-2034

Download a Free SampleTo learn more about this report.

Tuberculosis Testing Market Dynamics

01

Government TB Control Programs Drive Market

Government-led tuberculosis control programs support the procurement and distribution of diagnostic tests across public healthcare facilities. National screening initiatives, free testing services, and public health campaigns encourage healthcare centers to strengthen their diagnostic capacity and improve access to tuberculosis testing. These programs create sustained demand for testing kits, laboratory equipment, and diagnostic services, particularly in regions with established public healthcare networks.

02

High TB Disease Burden Sustains Demand Market

The substantial burden of tuberculosis cases across several countries creates a continued need for diagnostic testing in hospitals, clinics, and community health centers. Healthcare providers require regular screening services to identify suspected cases, confirm infections, and support timely treatment decisions. This demand encourages public and private healthcare facilities to maintain adequate supplies of diagnostic kits and strengthen laboratory testing capacity.

03

Impact Analysis of Key Drivers in Tuberculosis Testing Market

DriversMarket Impact

Government TB Control Programs Strengthen Testing Demand

National tuberculosis control initiatives support screening activities, diagnostic infrastructure, and testing access across public healthcare facilities.

High TB Disease Burden Supports Diagnostic Requirements

A substantial number of tuberculosis cases creates demand for routine screening and diagnostic services across hospitals, clinics, and community health centers.

Active Case-Finding Programs Improve Testing Coverage

Community-based screening and contact-tracing activities encourage testing among high-risk populations and support demand for diagnostic kits and laboratory services.

International Healthcare Funding Supports TB Diagnostics

Financial assistance from global health organizations and public health agencies supports diagnostic procurement, laboratory capacity, and testing programs in high-burden regions.

Need for Early TB Diagnosis Strengthens Screening Activities

Early identification of tuberculosis supports timely treatment decisions and encourages healthcare providers to conduct diagnostic testing among symptomatic and high-risk individuals.

01

High Cost of Advanced Tuberculosis Diagnostic Tests Limits Testing Access

Advanced tuberculosis diagnostic methods, particularly molecular tests, require specialized instruments, testing kits, and laboratory facilities, which increase diagnostic expenses. The high cost of equipment installation, consumables, and maintenance places financial pressure on public healthcare facilities and smaller diagnostic centers. These cost barriers restrict access to advanced testing solutions and limit their adoption in low-resource settings.

02

Limited Access to Diagnostic Infrastructure in Remote Areas Delays Testing

Remote and underserved regions often lack adequately equipped laboratories, trained diagnostic personnel, and reliable testing facilities. These infrastructure gaps make sample processing and timely result delivery difficult, particularly where patients must travel long distances to access diagnostic services. Limited testing availability delays tuberculosis detection and restricts the expansion of diagnostic services in underserved areas.

03

Impact Analysis of Key Restraints in Tuberculosis Testing Market

RestraintsMarket Impact

High Cost of Advanced Tuberculosis Diagnostic Tests

Expensive molecular testing platforms and specialized equipment limit access among low-resource healthcare facilities, restricting wider adoption.

Limited Access to Diagnostic Infrastructure in Remote Areas

Inadequate laboratory facilities, trained personnel, and testing equipment delay diagnosis and reduce testing availability in underserved regions.

Shortage of Skilled Laboratory Professionals

Limited availability of trained technicians and diagnostic specialists can affect testing capacity, result accuracy, and service delivery.

Diagnostic Limitations in Detecting Drug-Resistant Tuberculosis

Certain testing methods have limitations in identifying drug resistance, which can delay appropriate treatment decisions and reduce diagnostic effectiveness.

Complex Regulatory Approval and Quality Assurance Requirements

Strict validation, safety, and performance requirements increase development costs and can delay the introduction of new tuberculosis diagnostic technologies.

01

Point-of-Care TB Testing

Rural clinics, community health centers, mobile health units, and laboratories with limited infrastructure can use compact TB testing systems near the patient. Demand for decentralized testing creates revenue through portable analyzers, test cartridges, consumables, and service contracts. Companies such as Cepheid and Molbio Diagnostics offer portable or decentralized molecular diagnostic platforms relevant to this opportunity.

02

Multiplex Testing Offers Growth Opportunities

Hospitals, diagnostic laboratories, and outpatient clinics can use multiplex platforms to test for TB alongside other respiratory pathogens from a single patient sample. Broader testing menus can increase instrument utilization and create recurring revenue from panels, reagents, and consumables. Companies such as bioMérieux and QIAGEN offer multiplex respiratory testing technologies that support this opportunity.

Tuberculosis Testing Market Segmentation Analysis

By Diagnostic Test Type

The nucleic acid test segment accounted for a share of 24.9% in 2025, owing to its ability to detect genetic material with high accuracy and support the identification of infections at an early stage.

The drug resistance test segment is expected to register a CAGR of 6.21% during the forecast period, driven by the need to identify drug-resistant pathogens and guide appropriate treatment decisions.

Tuberculosis Testing Market Size By Segments

Request Customizationto receive a tailored report.

By End User

The hospital/clinic segment is expected to register a CAGR of 5.08% during the forecast period, supported by the extensive use of diagnostic testing for disease detection, patient assessment, and treatment planning.

The diagnostics/research segment is expected to register a CAGR of 5.72% during the forecast period, fueled by the need for specialized testing, laboratory-based disease analysis, and research activities.

Tuberculosis Testing Market Share By Segments

Speak to an Analystto discuss market opportunities.

Tuberculosis Testing Market Regional Outlook

North America Tuberculosis Testing Market

The North America tuberculosis testing market accounted for the largest regional share of 36.5% in 2025.

U.S. Tuberculosis Testing Market

The U.S. tuberculosis testing sector is supported by the use of interferon-gamma release assays, nucleic acid amplification tests, culture, and drug-susceptibility testing across clinical and public health laboratories. In March 2026, the U.S. Food and Drug Administration proposed a classification framework for qualitative Mycobacterium tuberculosis cell-mediated immune response assays, establishing special controls for these in-vitro diagnostic devices. This regulatory development supports standardized evaluation and oversight of blood-based tuberculosis testing technologies.

Canada Tuberculosis Testing Market

Canada’s diagnostic infrastructure supports tuberculosis detection through molecular assays, laboratory culture, and drug-resistance testing. In 2026, Public Health Ontario updated its laboratory testing pathway, replacing the discontinued GenoType MTBDRplus line-probe test with the BD MAX MDR-TB Assay for detecting tuberculosis complex and predicting rifampin and isoniazid resistance in positive cultures. This transition supports continued demand for molecular diagnostic platforms and resistance-testing capabilities.

North America Tuberculosis Testing Market Revenue Share 2025

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific Tuberculosis Testing Market

The Asia Pacific tuberculosis testing market is projected to register a CAGR of 6.74% during the forecast period, making it the fastest-growing market.

China Tuberculosis Testing Market

China’s tuberculosis testing landscape offers opportunities for molecular diagnostic platforms, rapid screening technologies, and drug-resistance testing. In March 2026, the World Health Organization issued new recommendations for near point-of-care molecular tests, tongue-swab sampling, and sputum pooling to improve testing accessibility and efficiency. These recommendations provide a framework for expanding diagnostic options and improving access to testing across healthcare settings.

India Tuberculosis Testing Market

India’s tuberculosis diagnostic ecosystem relies on molecular testing, microscopy, and laboratory-based drug-susceptibility assessment to support early detection and treatment decisions. The World Health Organization’s March 2026 recommendations on near point-of-care molecular tests, tongue-swab samples, and sputum pooling create opportunities to expand accessible testing approaches, particularly in settings where conventional sample collection and laboratory access present operational challenges.

Japan Tuberculosis Testing Market

Japan’s tuberculosis testing demand is supported by domestic screening programs, clinical diagnosis, and monitoring of imported cases. In September 2026, Japan’s Ministry of Health, Labour and Welfare announced an expansion of its pre-entry tuberculosis screening program, with Indonesia scheduled to enter the program in November 2026. The initiative supports demand for medical screening, laboratory confirmation, and diagnostic services for individuals subject to entry requirements.

Europe Tuberculosis Testing Market

The Europe tuberculosis testing market is projected to register a CAGR of 4.62% during the forecast period.

U.K. Tuberculosis Testing Market

The U.K. continues to emphasize early tuberculosis detection through targeted screening, laboratory diagnosis, and testing of at-risk populations. In March 2026, the UK Health Security Agency updated its tuberculosis screening guidance for professionals working with at-risk groups, including active case finding and pre-entry screening. These measures support demand for diagnostic tests, laboratory services, and screening technologies.

Germany Tuberculosis Testing Market

Germany’s tuberculosis diagnostic infrastructure is supported by laboratory testing, reference laboratory networks, and surveillance of drug-resistant infections. In March 2026, the European Centre for Disease Prevention and Control released an updated handbook on tuberculosis laboratory diagnostic methods across the European Union, reinforcing the importance of laboratory quality, standardized diagnostic procedures, and reference laboratory capabilities. These priorities support demand for molecular assays, culture systems, and drug-susceptibility testing.

Competitive Landscape

The tuberculosis testing market is moderately fragmented, with competition involving in-vitro diagnostic manufacturers, molecular diagnostics companies, clinical laboratory service providers, medical technology developers, and specialized infectious disease testing solution providers. The leading players in the market include Abbott Laboratories, Cepheid, and F. Hoffmann-La Roche, accounting 25–30% of the global tuberculosis testing market share.

Established players compete primarily on diagnostic accuracy, test sensitivity and specificity, regulatory approvals, turnaround time, product reliability, distribution networks, and integration with laboratory workflows. Emerging and specialized players in the tuberculosis testing market ecosystem compete through rapid molecular testing technologies, point-of-care diagnostic platforms, portable testing devices, automated sample processing, cost-effective screening solutions, and innovative assays that improve access to tuberculosis detection across resource-limited healthcare settings.

List of Key and Emerging Players in Tuberculosis Testing Market

Abbott Laboratories (U.S.)
Becton, Dickinson and Company (U.S.)
bioMérieux SA (France)
Cepheid (U.S.)
F. Hoffmann-La Roche AG (Switzerland)
Hain Lifescience GmbH (Germany)
Hologic, (U.S.)
QIAGEN N.V. (Netherlands)
AdvaCare Pharma (U.S.)
Thermo Fisher Scientific (U.S.)

Key Industry Developments

March 2026
The World Health Organization (WHO) recommended a new generation of near-point-of-care molecular TB diagnostic tests, together with tongue swab sampling and sputum pooling, enabling faster, lower-cost tuberculosis diagnosis and improved access in resource-limited settings.

Report Scope

Segmentation

By Diagnostic Test Type 7
  • Radiographic Test
  • Smear Microscopy
  • Culture-Based Test
  • Nucleic Acid Test
  • Cytokine Detection Test
  • Drug Resistance Test
  • Other Diagnostic Test Types
By End User 2
  • Hospital/Clinic
  • Diagnostics/Research

Geographies Covered

North America 2
  • U.S.
  • Canada
Europe 8
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Russia
  • Nordic
  • Benelux
APAC 7
  • China
  • Korea
  • Japan
  • India
  • Australia
  • Taiwan
  • South East Asia
Middle East and Africa 6
  • UAE
  • Turkey
  • Saudi Arabia
  • South Africa
  • Egypt
  • Nigeria
LATAM 5
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Colombia
Competitive Coverage Abbott Laboratories (U.S.) · Becton, Dickinson and Company (U.S.) · bioMérieux SA (France) · Cepheid (U.S.) · F. Hoffmann-La Roche AG (Switzerland)
Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Reportto Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The tuberculosis testing market size is valued at USD 2.18 Billion in 2026 and is projected to reach USD 3.35 Billion by 2034, at a CAGR of 5.5% during the forecast period 2026-2034.
North America dominated the market with a share of 36.5% in 2025.
The leading players in this market are Abbott Laboratories, Becton Dickinson & Company, BioMerieux SA, Cepheid, F. Hoffmann-La Roche AG.
The tuberculosis testing market is projected to grow at a CAGR of 5.5% during the forecast period of 2026 2034.
About the Author
Dhanashri Chandgude
Dhanashri Chandgude
Senior Research Associate

Dhanashri Chandgude is a healthcare research professional with over four years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.

Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.

Report Details
−
Trusted by Industry Leaders
LG ElectronicsAMCAD EngineeringKOBE STEEL LTD.Hindustan National Glass & Industries LimitedVoith GroupInternational PaperHansol PaperWhirlpool CorporationSonySamsung ElectronicsQualcommGoogleFiservVeto-PharmaNippon Becton DickinsonMerckArgon Medical DevicesAbbottAjinomotoDenonDoosanMeiji Seika Kaisha LtdLG ChemicalsLCY chemical groupBayerAirraneBASFToyota IndustriesNissan MotorsNeenahMitsubishiHyundai Motor CompanyHondaCRP Industries IncpewagLGEPanasonicLubrizol CorporationLeonardoJohnson & JohnsonHB FullerMITSUBISHI CHEMICALHyundai MobisAmazon
Request SampleOrder Report Now